Comparative effectiveness and safety of fluticasone-based versus beclometasone-based single-inhaler triple therapies in patients with chronic obstructive pulmonary disease: a population-based cohort study
This cohort study conducted in an Asian COPD population suggests that fluticasone/umeclidinium/vilanterol may be a preferred initial treatment option over beclometasone/glycopyrrolate/formoterol. While among patients who are able to maintain their therapies for ≥ 90 days, both treatments may demonstrate more comparable effectiveness and safety profiles.
Authors
- Sheng‐Wei Pan (ORCID: https://orcid.org/0000-0002-7400-6996)
- Yaa‐Hui Dong (ORCID: https://orcid.org/0000-0001-5336-4113)
- Ming-Ching Chen
- Hiraku Kumamaru (ORCID: https://orcid.org/0000-0002-9759-6191)
- Chun‐Yu Chen (ORCID: https://orcid.org/0000-0003-4284-8918)
- N. Tsai
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- The University of Tokyo (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- International Journal of Clinical Pharmacy
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1007/s11096-025-02037-4
- Citations
- 2
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04